Jardiance is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease.
In type 2 diabetes, Jardiance is used in adults whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another treatment for diabetes). It can also be used as an ‘add-on’ treatment to other diabetes medicines.
In chronic heart failure (a condition in which the heart does not pump blood around the body as well as it should), Jardiance is used in adults to treat symptoms of the disease. Jardiance is also used in adults with chronic kidney disease.
Jardiance contains the active substance empagliflozin.
Jardiance : EPAR - Summary for the public (PDF/125.77 KB)
First published: 16/06/2014
Last updated: 17/08/2023
Jardiance : EPAR - Risk-management-plan summary (PDF/2.64 MB)
First published: 14/09/2023
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Boehringer Ingelheim International GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
Binger Strasse 173
24/07/2023 Jardiance - EMEA/H/C/002677 - II/0074
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Drugs used in diabetes
Type 2 diabetes mellitus
Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered
- in addition to other medicinal products for the treatment of diabetes
For study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.
Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic kidney disease
Jardiance is indicated in adults for the treatment of chronic kidney disease.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 202228/01/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 201616/12/2016